Eventide Balanced Fund Class I
ETIMX
NASDAQ- -
USD
- -
- -
- -
- -
(- -)
Recent
price
- -
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Eventide Balanced Fund (ETIMX) is a diversified mutual fund managed by Eventide Asset Management, LLC that seeks current income while maintaining the potential for capital appreciation through a balanced approach between fixed income securities and equity income securities; it invests primarily in a broad universe of income-producing securities including dividend-paying equities, corporate bonds, government securities, and other fixed income instruments with at least 25% allocated to each asset class to achieve consistent total returns and lower volatility. The fund emphasizes bottom-up quality investing in companies that create value for stakeholders including customers, employees, suppliers, communities, and the environment, with tactical asset allocation favoring forward-looking opportunities in sectors such as industrials, utilities, financials, and technology; top holdings as of late 2025 include Trane Technologies plc, Arthur J. Gallagher & Co., The Williams Companies Inc., nVent Electric plc, and Nasdaq Inc. Class I shares (ETIMX) feature a minimum investment of $100,000, monthly distributions, and an expense ratio of approximately 0.76%, with related share classes including A (ETAMX), C (ETCMX), and N (ETNMX). Eventide Asset Management, LLC, founded in 2008 and headquartered in Boston, Massachusetts, operates the fund as part of its suite of mutual funds focused on values-based investing across core equity, growth, balanced, and bond strategies. Launched on July 15, 2015, the fund manages approximately $382 million in assets and benchmarks performance against the Bloomberg Mid Cap/Intermediate US Aggregate 50/50 TR Index. Recent developments at Eventide include the final close of its inaugural private investment vehicle, the Eventide Healthcare Innovation Fund I, LP, with $83 million in committed capital in May 2024 to target private biotech companies addressing unmet medical needs; portfolio adjustments such as a significant new stake in Beta Bionics Inc. in early 2025 and Frontdoor Inc. in late 2025; and ongoing 13F filings reflecting active positions in healthcare, industrials, and technology sectors. The fund serves individual and institutional investors seeking moderate allocation strategies in the U.S. market with no specified international geographic focus beyond domestic securities.